Companies: 10,795·Total market cap: $144.5T
Glaukos Corporation

Glaukos Corporation

GKOSNYSEHealthcare● Active
$125.00
+$3.31(+2.72%)
Market Cap$7.3B
P/E Ratio
52W High$148.11
52W Low$73.16
Overview

Glaukos Corporation (GKOS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

gkos · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Glaukos Corporation (GKOS) measures how much investors pay for each dollar of the company's trailing earnings. GKOS's current PE ratio of N/A is calculated by dividing its stock price of $125.00 by its TTM earnings per share of -$3.26.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
282.84x
FY2027 est. EPS $0.44
Based on 8 analysts
EPS (TTM)
-$3.26
TTM · diluted EPS
PEG Ratio
0.33
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Glaukos Corporation SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2012 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 190.8x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Devices · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Glaukos Corporation
Glaukos CorporationYou
GKOS
$7.3BN/A-$3.26
Arcellx, Inc.
Arcellx, Inc.
ACLX
$6.7BN/A-$4.07
Alkermes plc
Alkermes plc
ALKS
$7.1B19.07x$1.47
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
ARWR
$10.3BN/A-$0.01
Bausch + Lomb Corporation
Bausch + Lomb Corporation
BLCO
$5.5BN/A-$1.02
Bruker Corporation
Bruker Corporation
BRKR
$8.6BN/A-$0.06
iRhythm Technologies, Inc.
iRhythm Technologies, Inc.
IRTC
$3.6BN/A-$1.39

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 14 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-3.28
2024-12-31
FY2024
$-2.77
2023-12-31
FY2023
$-2.78
2022-12-31
FY2022
$-2.09
2021-12-31
FY2021
$-1.07
2020-12-31
FY2020
$-2.70
2019-12-31
FY2019
131.92x$0.41
2018-12-31
FY2018
$-0.37
2017-12-31
FY2017
$-0.00
2016-12-31
FY2016
249.76x$0.14

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Glaukos Corporation (GKOS) measures how much investors pay for each dollar of the company's trailing earnings. GKOS's current PE ratio of N/A is calculated by dividing its stock price of $125.00 by its TTM earnings per share of -$3.26.

PE Ratio = Stock Price ÷ EPS (TTM)
= $125.00 ÷ -$3.26 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

GKOS pe ratio · 6 questions

GKOS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $125.00 and TTM EPS of -$3.26. Data sourced from Financial Modeling Prep via GKOS's SEC 10-K and 10-Q filings.

GKOS PE ratioWhat is GKOS PE ratioCurrent PE ratio of GKOSGKOS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Glaukos Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08